VX-670 is named as a drug or biological intervention in 2 clinical trials in our UK and USA trial registers, none of which are currently recruiting. The lead sponsor is Vertex Pharmaceuticals Incorporated. Registered phases: Phase 1/2 and Phase 2. Conditions studied include Myotonic Dystrophy Type 1 (DM1).
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT06926621 | A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I (ClinicalTrials.gov ↗) Myotonic Dystrophy Type 1 (DM1) |
Phase 2 | By invitation |
| NCT06185764 | A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) (ClinicalTrials.gov ↗) Myotonic Dystrophy Type 1 (DM1) |
Phase 1/2 | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Myotonic Dystrophy Type 1 (DM1) | 2 |
| Lead sponsor | Trials |
|---|---|
| Vertex Pharmaceuticals Incorporated | 2 |
| Register | VX-670 trials |
|---|---|
| Clinical trials in UK | 2 |
| Clinical trials in USA | 2 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how VX-670 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists VX-670 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.